임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

12건 표시

4상모집 중· Lacunar Stroke
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
협력: 다케다
상세 →NCT07111559
4상모집 중· Ulcerative Colitis
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
리드: 다케다
상세 →NCT06581328
4상모집 중· Colorectal Cancer
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
리드: 다케다
상세 →NCT06562543
4상모집 중· Crohn's Disease
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
협력: 다케다
상세 →NCT06180382
4상모집 중· Hodgkin Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
리드: 다케다
상세 →NCT06831370
4상모집 중· Moderately to Severely Active Crohn's Disease
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
협력: 다케다
상세 →NCT06257706
4상모집 중· Ulcerative Colitis
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
리드: 다케다
상세 →NCT06095128
4상모집 중· Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
리드: 다케다
상세 →NCT06045754
4상모집 중· Fabry Disease
A Study of Replagal in Children and Adults With Fabry Disease in India
협력: 다케다
상세 →NCT05067868
4상모집 중단 (진행 중)· Crohn's Disease
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
리드: 다케다
상세 →NCT04809363
4상모집 중단 (진행 중)· Hemophilia A With Inhibitor
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
협력: 다케다
상세 →NCT04205175
4상모집 중단 (진행 중)· Colitis, Ulcerative
Determination of the Optimal Treatment Target in Ulcerative Colitis
협력: 다케다
상세 →NCT04259138

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.